New drug shields bone marrow during lung cancer chemo
NCT ID NCT06370416
First seen Feb 01, 2026 · Last updated Apr 28, 2026 · Updated 11 times
Summary
This study tests whether giving the drug trilaciclib before chemotherapy can prevent dangerous drops in blood cell counts (bone marrow suppression) in people with advanced non-small cell lung cancer. About 41 participants will receive trilaciclib before their standard platinum-based chemo. The main goal is to see if it reduces severe neutropenia (low infection-fighting white blood cells).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Tumor Hospital
Zhengzhou, Henan, 450000, China
Conditions
Explore the condition pages connected to this study.